Infectious Diseases

Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail Dcri-2400 Pratt Street, Room 0311-BOX 3850, Durham, NC 27710
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Grants

Publications

Sulkowski, MS, Rodriguez-Torres, M, Lalezari, JP, Fessel, WJ, Mounzer, K, Shuhart, MC, Luetkemeyer, A, Asmuth, DM, Gaggar, A, Symonds, WT, McHutchison, JG, Naggie, S, and Dieterich, DT. "All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1)." October 2013.

Scholars@Duke

Osinusi, A, and Naggie, S. "Boceprevir for HCV in patients with HIV: where next?." Lancet Infect Dis 13, no. 7 (July 2013): 563-564.

PMID
23768748
Full Text

Osinusi, A, and Naggie, S. "Boceprevir for HCV in patients with HIV: Where next?." The Lancet Infectious Diseases 13, no. 7 (2013): 563-564.

Full Text

Naggie, S. "Management of hepatitis C virus infection: the basics." Top Antivir Med 20, no. 5 (December 2012): 154-161. (Review)

PMID
23363693
Scholars@Duke

Jones, L, Piercy, D, Naggie, S, and Abdelmalek, M. "Drug-Induced Idiopathic Portal Hypertension Mimicking "Cryptogenic" Cirrhosis in a HIV Patient." October 2012.

Scholars@Duke

Osinusi, A, Chary, A, Winters, MA, Naggie, S, Masur, H, Polis, MA, Kottilil, S, and Holodniy, M. "IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin." J Med Virol 84, no. 10 (October 2012): 1522-1527.

PMID
22930497
Full Text

Naggie, S, Osinusi, A, Himmel, T, Lucas, J, Thompson, JW, Dubois, LG, Moseley, MA, Clark, PJ, Kottilil, S, and Patel, K. "Targeted proteomics signature identifies corticosteroid binding globulin peptides as highly predictive of treatment response in IL28B unfavorable genotype patients." October 2012.

Scholars@Duke

Clark, PJ, Santoro, R, Piazzolla, V, Mottola, L, Bacca, D, Dello Iacono, N, Grimaldi, S, Quarta, A, Urban, TJ, Naggie, S, Patel, K, Thompson, AJ, Muir, AJ, and Mangia, A. "Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C." October 2012.

Scholars@Duke

Clark, PJ, Thompson, AJ, Zhu, Q, Vock, DM, Zhu, M, Patel, K, Harrison, SA, Naggie, S, Ge, D, Tillmann, HL, Urban, TJ, Shianna, K, Fellay, J, Goodman, Z, Noviello, S, Pedicone, LD, Afdhal, N, Sulkowski, M, Albrecht, JK, Goldstein, DB, McHutchison, JG, and Muir, AJ. "Erratum: The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis c infection (Digestive Diseases and Sciences (2012) 57 (2479))." Digestive Diseases and Sciences 57, no. 9 (September 1, 2012): 2479-null.

Full Text

Norton, BL, Park, L, McGrath, LJ, Proeschold Bell, RJ, Muir, AJ, and Naggie, S. "Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection." Aids Patient Care and Stds 26, no. 9 (September 2012): 541-545.

PMID
22860997
Full Text

Pages